EUVIMEDEUVIMED entdecken
Crossref

JAK2 V617F mutation and circulating extracellular vesicles in essential thrombocythemia

Mohamed Hussam Aswad, Jarmila Kissova, Petra Ovesna, Lucie Říhová, Miroslav Penka

Clinical Hemorheology and Microcirculation · 2023

DOI: 10.3233/ch-221678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Hemorheology and Microcirculation, 2023. Verfasst von Mohamed Hussam Aswad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic. Hauptthemen laut MEDLINE: Janus Kinase 2, Myeloproliferative Disorders, Thrombocythemia, Essential, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients’ mortality. Studies have identified JAK2 V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2 V617F mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2 V617F -positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7–83.7], P = 0.013), and that JAK2 V617F mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47–8.62], P = 0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2 V617F mutation ( P = 0.018, P = 0.024, respectively). In conclusion, our results support the role of JAK2 V617F mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Myeloproliferative DisordersThrombocythemia, EssentialThrombosisHumansBlood PlateletsMutation

Stichwörter der Autor:innen

Essential thrombocythemiaJAK2V617F mutationextracellular vesiclesrisk factorthrombosis

Substanzen

Janus Kinase 2

Autor:innen und Institutionen

  • Department of Clinical Hematology, Faculty of Medicine, University Hospital Brno, Brno, Czech Republic.
  • Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Zitieren

APA

Aswad, M. H., Kissova, J., Ovesna, P., Říhová, L., & Penka, M. (2023). JAK2 V617F mutation and circulating extracellular vesicles in essential thrombocythemia. Clinical Hemorheology and Microcirculation. https://doi.org/10.3233/ch-221678

Vancouver

Aswad MH, Kissova J, Ovesna P, Říhová L, Penka M. JAK2 V617F mutation and circulating extracellular vesicles in essential thrombocythemia. Clinical Hemorheology and Microcirculation. 2023. doi:10.3233/ch-221678

BibTeX
@article{Aswad2023,
  author = {Aswad, Mohamed Hussam and Kissova, Jarmila and Ovesna, Petra and Říhová, Lucie and Penka, Miroslav},
  title = {JAK2 V617F mutation and circulating extracellular vesicles in essential thrombocythemia},
  journal = {Clinical Hemorheology and Microcirculation},
  year = {2023},
  doi = {10.3233/ch-221678}
}
Kostenlos starten →